[1] A. T. Chan, "Nasopharyngeal carcinoma," Ann. Oncol. Suppl 7(vii), 308-312 (2010).

[2] J. Guigay, "Advances in nasopharyngeal carcinoma," Curr. Opin. Oncol. 20(3), 264-269 (2008).

[3] Z. Huang, "A review of progress in clinical photodynamic therapy," Technol. Cancer Res. Treat. 4(3), 283-293 (2005).

[4] M. A. Wildeman, H. J. Nyst, B. Karakullukcu, B. I. Tan, "Photodynamic therapy in the therapy for recurrent/persistent nasopharyngeal cancer," Head Neck Oncol. 1(40), 1-6 (2009).

[5] P. Agostinis, K. Berg, K. A. Cengel, T. H. Foster, A. W. Girotti, S. O. Gollnick, S. M. Hahn, M. R. Hamblin, A. Juzeniene, D. Kessel, M. Korbelik, J. Moan, P. Mroz, D. Nowis, J. Piett, B. C. Wilson, J. Golab, "Photodynamic therapy of cancer: an update," CA Cancer J. Clin. 61(4), 250-281 (2011).

[6] Z. Q. Sun, G. Y. Luo, "Photodynamic therapy for recurrent nasopharyngeal carcinoma after radiotherapy (An analysis of 191 cases)," Chin. J. Laser Med. Surg. 5, 134-136 (1996) (in Chinese).

[7] M. C. Tong, C. A. van Hasselt, J. K. Woo, "Preliminary results of photodynamic therapy for recurrent nasopharyngeal carcinoma," Eur. Arch. Otorhinolaryngol. 253(3), 189-192 (1996).

[8] L. Li, R. Luo, W. Liao, M. Zhang, Y. Luo, J. Miao, "Clinical study of Photofrin photodynamic therapy for the treatment of relapse nasopharyngeal carcinoma," Photodiag. Photodyn. Ther. 3(4), 266-271 (2006).

[9] J. Bedwell, A. J. MacRobert, D. Phillips, S. G. Bown, "Fluorescence distribution and photodynamic effect of ALA-induced PP IX in the DMH rat colonic tumour model," Br. J. Cancer 65(6), 818-824 (1992).

[10] C. S. Betz, J. P. Lai, W. Xiang, P. Janda, P. Heinrich, H. Stepp, R. Baumgartner and A. Leunig, "In vitro photodynamic therapy of nasopharyngeal carcinoma using 5-aminolevulinic acid," Photochem. Photobiol. Sci. 1(5), 315-319 (2002).

[11] V. Manivasager, P. W. Heng, J. Hao, W. Zheng, K. C. Soo, M. Olivo, "Macro-microscopic fluorescence imaging of human NPC xenografts in a murine model using topical vs intravenous administration of 5-aminolevulinic acid," Int. J. Oncol. 21(5), 1003-1007 (2002).

[12] V. Manivasager, K. K. Yee, P. W. Heng, K. C. Soo, M. Olivo, "A study comparing endogenous protoporphyrin IX induced by 5-ALA and ALA-methyl ester with exogenous PpIX and PpIX dimethyl ester in photodynamic diagnosis of human nasopharyngeal carcinoma xenografts," Int. J. Oncol. 29(4), 997-1002 (2002).

[13] N. Fotinos, M. A. Campo, F. Popowycz, R. Gurny, N. Lange, "5-Aminolevulinic acid derivatives in photomedicine: Characteristics, application and perspectives," Photochem. Photobiol. 82(4), 994-1015 (2006).

[14] S. B. Brown, "The role of light in the treatment of non-melanoma skin cancer using methyl aminolevulinate," J.Dermatolog.Treat. 14(Suppl. 3), 11-14 (2003).

[15] J. A. Witjes, J. Douglass, "The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer," Nat. Clin. Pract. Urol. 4(10), 542-549 (2007).

[16] D. P. Huang, J. H. Ho, Y. F. Poon, E. C. Chew, D. Saw, M. Lui, C. L. Li, L. S. Mak, S. H. Lai, W. H. Lau, "Establishment of a cell line (NPC/HK1) from a differentiated squamous carcinoma of the nasopharynx," Int. J. Cancer 26(2), 127-132 (1980).

[17] Z. Sizhong, G. Xiukung, Z. Yi, "Cytogenetic studies on an epithelial cell line derived from poorly differentiated nasopharyngeal carcinoma," Int. J. Cancer 31(5), 587-590 (1983).

[18] E. A. Hryhorenko, K. Rittenhouse-Diakun, N. S. Harvey, J. Morgan, C. C. Stewart and A. R. Oseroff, "Characterization of endogenous protoporphyrin IX induced by delta-aminolevulinic acid in resting and activated peripheral blood lymphocytes by four-color flow cytometry," Photochem. Photobiol. 67(5), 565-572 (1998).

[19] R. W. K. Wu, E. S. M. Chu, C. M. N. Yow, J. Y. Chen, "Photodynamic effects on nasopharyngeal carcinoma (NPC) cells with 5-aminolevulinic acid or its hexyl ester," Cancer Lett. 242(1), 112-119 (2006).

[20] C. M. N. Yow, J. Y. Chen, N. K. Mam, N. H. Cheung, A. W. Leung, "Cellular uptake, subcellular, localization and photodamaging effect of temoporfin (mTHPC) in nasopharyngeal carcinoma cells: comparison with hematoporphyrin derivative (HPD)," Cancer Lett. 157(2), 123-131 (2000).

[21] P. L. Olive, J. P. Banath, "Induction and rejoining of radiation-induced DNA single-strand breaks: "tail moment" as a function of position in the cell cycle," Mutation Res. 294(3), 275-283 (1993).

[22] S. L. Gibson, J. J. Havens, T. H. Foster, R. Hilf, "Time-dependent intracellular accumulation of delta-aminolevulinic acid, induction of porphyrin synthesis and subsequent phototoxicity," Photochem. Photobiol. 65(3), 416-421 (1997).

[23] J. M. Gaullier, K. Berg, Q. Peng, H. Anholt, P. K. Selbo, L. W. Ma, J. Moan, "Use of 5-aminolevulinic acid esters to improve photodynamic therapy on cells in culture," Cancer Res. 57(8), 1481-1486 (1997).

[24] K. P. Uberriegler, E. Banieghbal, B. Krammer, "Subcellular damage kinetics within co-cultivated WI38 and VA13-transformed WI38 human fibroblasts following 5-aminolevulinic acid-induced protoporphyrin IX formation," Photochem. Photobiol. 62(6), 1052-1057 (1995).

[25] B. Li, Z. Chen, L. Liu, Z. Huang, Z. Huang, S. Xie, "Differences in sensitivity to HMME-mediated photodynamic therapy between EBVt C666-1 and EBV- CNE2 cells," Photodiagnosis Photodyn. Ther. 7(3), 204-209 (2010).

[26] C. M. Yow, C. K. Wong, Z. Huang, R. J. Ho, "Study of the efficacy and mechanism of ALA-mediated photodynamic therapy on human hepatocellular carcinoma cell," Liver Int. 27(2), 201-208 (2007).

[27] R. W. Wu, C. M. Yow, C. K. Wong, Y. H. Lam, "Photodynamic therapy (PDT) — Initiation of apoptosis via activation of stress-activated p38 MAPK and JNK signal pathway in H460 cell lines," Photodiagnosis Photodyn. Ther. 8(3), 254-263 (2011).

[28] J. M. Gaullier, M. Gèze, R. Santus, T. Sa e Melo, J. C. Mazière, M. Bazin, P. Morlière, L. Dubertret, "Subcellular localization of and photosensitization by protoporphyrin IXhuman keratinocytes and fibroblasts cultivated with 5-aminolevulinic acid," Photochem. Photobiol. 62(1), 114-122 (1995).

[29] B. C. Wilson, M. Olivo, G. Singh, "Subcellular localization of Photofrin, aminolevulinic acid, photodynamic cross-resistance in vitro in radiationinduced fibrosarcoma cells sensitive or resistant to photofrin-mediated photodynamic therapy," Photochem. Photobiol. 65(1), 166-176 (1997).

[30] L. Henderson, A. Wolfreys, J. Fedyk, C. Bourner, S. Windebank, "The ability of the Comet assay to discriminate between genotoxins, cytotoxins," Mutagenesis 13(1), 89-94 (1998).

[31] E. S. Chu, R. W. Wu, C. M. Yow, T. K. Wong, J. Y. Chen, "The cytotoxic, genotoxic potential of 5-aminolevulinic acid on lymphocytes: A comet assay study," Cancer Chemother. Pharmacol. 58(3), 408-414 (2006).

[32] R. Musiol, M. Serda, J. Polanski, "Prodrugs in photodynamic anticancer therapy," Curr. Pharm. Des. 17(32), 3548-3559 (2011).